Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Goodbye ‘340B,’ Hello ‘Outpatient Drug Discount Program’ In House Reform Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

House Commerce Committee members are drafting legislation to make numerous significant changes to the 340B drug discount program, including the definition of eligible patients, new reporting and auditing requirements for providers and drug manufacturers, rules for contract pharmacies – and a new user-fee program for participating health care providers.

You may also be interested in...



340B Reform May Return To Capitol Hill: Hearings Will Play To New HRSA Leadership

Rep. Chris Collins (R-NY) plans to introduced a bill to reform the 340B drug discount program in the coming weeks, and says he has a commitment from the House Energy & Commerce Committee leadership to consider the bill in hearings over the summer; that in turn may help shape HRSA’s oversight of the program in the Trump Administration.

340B Drug Discount Program Hits A Turning Point, But In Which Direction?

Long-awaited “mega-guidance” sets boundaries on discount and makes big changes for HIV drugs – and could mean the beginning of the end of the scrutiny of the program. A legislative proposal floated in the context of the “21st Century Cures” bill might move things in a different direction.

340B Needs Legislative Fix For Overspending On Medicare Patients, GAO Says

Drug discount program creates financial incentive for participating hospitals to prescribe more drugs or more expensive drugs reimbursed by Medicare Part B, resulting in 'substantially higher' spending, a GAO report says.

Related Content

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel